Arrhythmias & electrophysiology
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe
Authors' conclusion
North American ARVC patients were substantially more likely than Europeans to receive primary prevention ICDs across all arrhythmic risk strata. A lower rate of ICD implantation in Europe was not associated with a higher rate of VA events in those without ICDs.
Study context
- Population
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) patients without prior ventricular arrhythmia (VA), clinical registries in Europe and North America, stratified by predicted VA risk (low <10%/5 years, intermediate 10%-25%/5 years, high >25%/5 years)
- Participants
- 1,098 patients
- Exposure
- North America vs Europe
- Outcome
- Primary prevention ICD implantation and survival free from sustained VA (including appropriate ICD therapy)
- Follow-up
- Median 5.1 years
Methodological detailsmulticentre registries, 11 countries
- Multicentre registries, 11 countries
Main finding
As reported in the abstract
North America vs EuropeHazard ratio (95% CI)
ICD implantation, adjusted for baseline risk factors
3.1(2.5–3.8)
Incident sustained VA, adjusted
1.4(1.1–1.8)
- Primary prevention ICD (overall)
- 554 (50.5%)
- First VA event (overall)
- 286 (26.0%)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Incident sustained VA in patients without ICDs (subgroup) | 2.1 (1.3–3.4) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe. Eur Heart J. Published 9 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →